Assess whether biosimilarity is analytically justified from CMC comparability

Situation

An inspector asking for batch records you cannot produce this week put CMC comparability package for a site change in front of RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study. This Pharma & Life Sciences / FDA Response and Labeling close is biosimilarity is analytically justified from CMC comparability package for a site change, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

Decision

RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• The population in CMC comparability package for a site change is the one an inspector asking for batch records you cannot produce this week named, so Proceed under protocol follows for this FDA Response and Labeling file.
• The population in CMC comparability package for a site change is adjacent only to an inspector asking for batch records you cannot produce this week; Pause the pathway is the honest Pharma & Life Sciences call.
• A 505(b)(2) program relying on literature plus a bridging study already contained an inspector asking for batch records you cannot produce this week before CMC comparability package for a site change arrived; no new FDA Response and Labeling path.
• Provenance on CMC comparability package for a site change after an inspector asking for batch records you cannot produce this week is broken; do not pick Proceed under protocol or Pause the pathway yet.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• Check whether CMC comparability package for a site change supports the labeled claim RWE evidence-strategy director would keep.
• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• For this Pharma & Life Sciences FDA Response and Labeling file, read CMC comparability package for a site change against an inspector asking for batch records you cannot produce this week and write the one fact that would move biosimilarity is analytically justified for RWE evidence-strategy director.